Downloads: 1
[cbd130]:
/
covid-liver.csv
| # | Cancer | Year | Month | Bleed | Mode_Presentation | Age | Gender | Etiology | Cirrhosis | Size | HCC_TNM_Stage | HCC_BCLC_Stage | ICC_TNM_Stage | Treatment_grps | Survival_fromMDM | Alive_Dead | Type_of_incidental_finding | Surveillance_programme | Surveillance_effectiveness | Mode_of_surveillance_detection | Time_diagnosis_1st_Tx | Date_incident_surveillance_scan | PS | Time_MDM_1st_treatment | Time_decisiontotreat_1st_treatment | Prev_known_cirrhosis | Months_from_last_surveillance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Y | Prepandemic | 1 | N | Surveillance | 68 | M | NAFLD | Y | 22 | II | A | NA | Ablation | 32.73 | Alive | NA | Y | Consistent | US | 0.47 | NA | 0 | 0.7 | NA | Y | 7.333333333 |
| 2 | Y | Prepandemic | 1 | N | Surveillance | 70 | M | ARLD | Y | 40 | I | D | NA | Supportive care | 3.03 | Dead | NA | Y | Consistent | US | NA | NA | 2 | NA | NA | Y | 4.033333333 |
| 3 | Y | Prepandemic | 1 | N | Surveillance | 64 | M | ARLD | Y | 52 | IV | B | NA | Medical | 14.97 | Dead | NA | Y | Consistent | US | NA | NA | 0 | NA | NA | Y | 5.9 |
| 4 | Y | Prepandemic | 1 | N | Incidental | 73 | M | ARLD | Y | 80 | IV | C | NA | Supportive care | 1.4 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 2 | NA | NA | Y | NA |
| 5 | Y | Prepandemic | 1 | N | Incidental | 66 | F | ARLD | Y | 60 | I | 0 | NA | Supportive care | 32.5 | Alive | Secondary care�acute | N | NA | NA | NA | NA | 0 | NA | NA | Y | NA |
| 6 | Y | Prepandemic | 1 | N | Incidental | 70 | M | NAFLD | Y | 24 | IIIA+IIIB | C | NA | Supportive care | 3.03 | Dead | Secondary care�acute | Y | Consistent | NA | NA | NA | 2 | NA | NA | Y | 3 |
| 7 | Y | Prepandemic | 1 | N | Incidental | 73 | M | NAFLD | Y | 28 | II | A | NA | TACE | 32.5 | Alive | Primary care�routine | N | NA | NA | 3.2 | NA | 0 | 3 | NA | Y | NA |
| 8 | Y | Prepandemic | 1 | N | Incidental | 67 | M | NAFLD | N | 45 | I | A | NA | TACE | 26.4 | Dead | Primary care�routine | N | NA | NA | 1.07 | NA | 0 | 1.4 | NA | N | NA |
| 9 | Y | Prepandemic | 1 | N | Surveillance | 57 | M | HCV | Y | 33 | I | B | NA | TACE | 32.27 | Alive | NA | Y | Consistent | US | 1.53 | NA | 1 | 1.53 | 0.8 | Y | 6.633333333 |
| 10 | Y | Prepandemic | 1 | N | Incidental | 75 | M | NAFLD | Y | 80 | IIIA+IIIB | D | NA | Supportive care | 4.73 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 11 | Y | Prepandemic | 1 | N | Incidental | 81 | F | No established CLD | N | 100 | I | B | NA | SIRT | 24.4 | Dead | Primary care�routine | N | NA | NA | 2.07 | NA | 0 | 2.7 | NA | N | NA |
| 12 | Y | Prepandemic | 1 | N | Surveillance | 82 | M | NAFLD | N | 27 | IV | C | NA | Supportive care | 3.1 | Dead | NA | Y | Consistent | AFP alone | NA | NA | 2 | NA | NA | Y | 4.266666667 |
| 13 | Y | Prepandemic | 1 | N | Surveillance | 74 | M | NAFLD | Y | 19 | II | C | NA | TACE | 23.17 | Dead | NA | Y | Consistent | US | 3.83 | NA | 2 | 7.23 | NA | Y | 6.233333333 |
| 14 | Y | Prepandemic | 1 | N | Incidental | 76 | M | NAFLD | N | 150 | IIIA+IIIB | C | NA | Supportive care | 4.8 | Dead | Primary care�routine | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 15 | Y | Prepandemic | 2 | N | Surveillance | 66 | M | ARLD | Y | 23 | IIIA+IIIB | A | NA | Medical | 15.53 | Dead | NA | Y | Consistent | US | 12.53 | NA | 1 | 4.4 | NA | Y | 6.3 |
| 16 | Y | Prepandemic | 2 | N | Incidental | 78 | F | NAFLD | N | 40 | I | B | NA | Medical | 13.87 | Dead | Secondary care�routine | N | NA | NA | 2.23 | NA | 1 | 2.23 | 0.23 | N | NA |
| 17 | Y | Prepandemic | 2 | N | Surveillance | 82 | F | PBC/AIH | Y | 19 | I | 0 | NA | Supportive care | 31.83 | Alive | NA | Y | Consistent | US | NA | NA | 0 | NA | NA | Y | 5.333333333 |
| 18 | Y | Prepandemic | 2 | N | Symptomatic | 71 | F | ARLD | Y | 54 | I | D | NA | Supportive care | 7.1 | Dead | NA | N | NA | NA | NA | NA | 0 | NA | NA | Y | NA |
| 19 | Y | Prepandemic | 2 | N | Symptomatic | 66 | M | NAFLD | N | 110 | IIIA+IIIB | B | NA | SIRT | 7.2 | Dead | NA | N | NA | NA | 3.2 | NA | 1 | 3.23 | 1.2 | N | NA |
| 20 | Y | Prepandemic | 2 | N | Incidental | 73 | M | NAFLD | Y | 14 | II | A | NA | Ablation | 31.83 | Alive | Primary care�acute | N | NA | NA | NA | NA | 0 | 0.93 | 0.23 | N | NA |
| 21 | Y | Prepandemic | 2 | N | Incidental | 86 | M | NAFLD | Y | 55 | II | C | NA | TACE | 16.1 | Dead | Secondary care�acute | N | NA | NA | 3.17 | NA | 2 | 4.07 | NA | N | NA |
| 22 | Y | Prepandemic | 2 | N | Surveillance | 77 | M | ARLD | Y | 11 | I | D | NA | Supportive care | 11.3 | Dead | NA | Y | Consistent | US | NA | NA | 1 | NA | NA | Y | 4.166666667 |
| 23 | Y | Prepandemic | 2 | N | Surveillance | 57 | M | ARLD | Y | 30 | IIIA+IIIB | D | NA | Supportive care | 7.03 | Dead | Secondary care�acute | Y | Consistent | US | NA | NA | 2 | NA | NA | Y | 4.033333333 |
| 24 | N | Prepandemic | 2 | NA | Surveillance | 64 | F | PBC/AIH | Y | 22 | I | C | II | Ablation | 31.77 | Alive | NA | Y | Consistent | AFP alone | 1.6 | NA | 2 | 1.6 | NA | Y | 3.766666667 |
| 25 | Y | Prepandemic | 2 | N | Incidental | 85 | M | HH | N | 90 | IIIA+IIIB | C | NA | Medical | 31.13 | Alive | Secondary care�acute | N | NA | NA | 1.63 | NA | 0 | 2.03 | NA | NA | NA |
| 26 | Y | Prepandemic | 2 | N | Surveillance | 73 | M | ARLD | Y | 70 | IIIA+IIIB | C | NA | Supportive care | 8.77 | Dead | NA | Y | Consistent | AFP alone | NA | NA | 3 | NA | NA | Y | 2.566666667 |
| 27 | Y | Prepandemic | 2 | N | Incidental | 78 | M | NAFLD | N | 28 | I | A | NA | TACE | 31.13 | Alive | Secondary care�routine | N | NA | NA | 2.03 | NA | 0 | 5 | NA | N | NA |
| 28 | Y | Prepandemic | 3 | N | Surveillance | 76 | M | NAFLD | Y | 45 | I | A | NA | TACE | 30.9 | Alive | NA | Y | Consistent | US | 3.47 | NA | 0 | 10.23 | NA | Y | 5.8 |
| 29 | Y | Prepandemic | 3 | N | Incidental | 54 | M | NAFLD | Y | 20 | I | A | NA | Ablation | 30.9 | Alive | Primary care�acute | N | NA | NA | 2.07 | NA | 0 | 2.07 | 2.07 | N | NA |
| 30 | Y | Prepandemic | 3 | N | Surveillance | 72 | M | ARLD | Y | 24 | I | C | NA | Ablation | 13 | Dead | NA | Y | Consistent | AFP alone | 3.87 | NA | 1 | 3.9 | NA | Y | 3.2 |
| 31 | Y | Prepandemic | 3 | N | Symptomatic | 63 | M | ARLD | Y | 44 | IIIA+IIIB | A | NA | Supportive care | 8.97 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | Y | NA |
| 32 | Y | Prepandemic | 3 | N | Incidental | 67 | F | PBC/AIH | Y | 70 | IV | C | NA | Supportive care | 0.13 | Dead | Secondary care�routine | N | NA | NA | NA | NA | 1 | NA | NA | Y | NA |
| 33 | Y | Prepandemic | 3 | N | Incidental | 84 | M | No established CLD | N | 150 | I | C | NA | Supportive care | 1.27 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 2 | NA | NA | N | NA |
| 34 | Y | Prepandemic | 3 | N | Symptomatic | 55 | F | HCV | Y | 40 | II | C | NA | Supportive care | 12.1 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 35 | Y | Prepandemic | 3 | N | Incidental | 68 | M | ARLD | Y | 16 | IIIA+IIIB | C | NA | Supportive care | 0.9 | Dead | Primary care�routine | N | NA | NA | NA | NA | 0 | NA | NA | N | NA |
| 36 | Y | Prepandemic | 3 | N | Symptomatic | 66 | M | No established CLD | N | NA | IV | D | NA | Supportive care | 0 | Dead | NA | N | NA | NA | NA | NA | 4 | NA | NA | N | NA |
| 37 | Y | Prepandemic | 3 | N | Surveillance | 54 | M | ARLD | Y | 35 | II | C | NA | TACE | 29.3 | Dead | NA | Y | Missed | US | 1.77 | NA | 1 | 2.23 | NA | Y | 58.8 |
| 38 | Y | Prepandemic | 3 | N | Symptomatic | 89 | M | NAFLD | Y | 20 | I | A | NA | TACE | 21.73 | Dead | NA | N | NA | NA | NA | NA | 1 | 3.37 | 1.4 | N | NA |
| 39 | Y | Prepandemic | 3 | N | Incidental | 75 | M | ARLD | Y | 94 | I | C | NA | SIRT | 30.2 | Alive | Primary care�routine | N | NA | NA | 3.13 | NA | 1 | 2.67 | NA | Y | NA |
| 40 | Y | Prepandemic | 3 | N | Surveillance | 87 | F | NAFLD | Y | 48 | IIIA+IIIB | B | NA | Supportive care | 5.23 | Dead | NA | Y | Consistent | US | NA | NA | 0 | NA | NA | Y | 9.833333333 |
| 41 | Y | Prepandemic | 3 | N | Incidental | 73 | M | NAFLD | Y | 70 | IIIA+IIIB | C | NA | Supportive care | 4.23 | Dead | Secondary care�acute | Y | Consistent | NA | NA | NA | 2 | NA | NA | Y | 1.533333333 |
| 42 | Y | Prepandemic | 4 | N | Surveillance | 77 | F | NAFLD | Y | 22 | II | B | NA | TACE | 24.4 | Dead | NA | Y | Consistent | US | 0.87 | NA | 1 | 0.87 | 0.87 | Y | 5.8 |
| 43 | Y | Prepandemic | 4 | N | Surveillance | 70 | F | ARLD | Y | 10 | I | A | NA | Ablation | 29.77 | Alive | NA | Y | Consistent | US | NA | NA | 1 | 1.63 | 1.6 | Y | 6.033333333 |
| 44 | Y | Prepandemic | 4 | N | Surveillance | 77 | M | ARLD | Y | 28 | I | A | NA | Ablation | 29.77 | Alive | NA | Y | Consistent | US | NA | NA | 2 | 0.83 | 0.4 | Y | 5.233333333 |
| 45 | Y | Prepandemic | 4 | N | Incidental | 69 | M | ARLD | N | 40 | I | A | NA | TACE | 29.77 | Alive | Secondary care�acute | Y | Consistent | NA | 2.6 | NA | 0 | 3.47 | NA | Y | 6 |
| 46 | Y | Prepandemic | 4 | N | Surveillance | 53 | M | ARLD | Y | 100 | IV | C | NA | Supportive care | 0.97 | Dead | NA | Y | Consistent | US | NA | NA | 0 | NA | NA | Y | 7.533333333 |
| 47 | Y | Prepandemic | 4 | N | Surveillance | 43 | M | ARLD | Y | 16 | I | A | NA | OLTx | 29.77 | Alive | NA | Y | Consistent | US | NA | NA | 0 | 15 | 7.43 | Y | 5.766666667 |
| 48 | Y | Prepandemic | 4 | N | Surveillance | 81 | M | ARLD | Y | 30 | I | B | NA | TACE | 29.77 | Alive | NA | Y | Consistent | AFP alone | NA | NA | 2 | 8.13 | 1.03 | Y | 6.733333333 |
| 49 | Y | Prepandemic | 4 | N | Symptomatic | 75 | M | ARLD | Y | NA | IV | C | NA | Supportive care | 4.4 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 50 | Y | Prepandemic | 4 | N | Symptomatic | 65 | M | HCV | Y | 100 | IIIA+IIIB | D | NA | Supportive care | 4.33 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 51 | Y | Prepandemic | 4 | N | Symptomatic | 71 | M | NAFLD | Y | 120 | IIIA+IIIB | B | NA | Supportive care | 5.07 | Dead | NA | N | NA | NA | NA | NA | NA | NA | NA | N | NA |
| 52 | Y | Prepandemic | 4 | N | Surveillance | 64 | M | ARLD | Y | 100 | IIIA+IIIB | D | NA | Supportive care | 0.17 | Dead | NA | Y | Consistent | US | NA | NA | 2 | NA | NA | Y | 8.466666667 |
| 53 | Y | Prepandemic | 4 | N | Symptomatic | 82 | F | NAFLD | Y | 45 | I | D | NA | Supportive care | 1.33 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | Y | NA |
| 54 | Y | Prepandemic | 4 | N | Surveillance | 41 | F | ARLD | Y | 11 | I | C | NA | Ablation | 29.3 | Alive | NA | Y | Inconsistent | US | 13.57 | NA | 1 | 1.6 | 1.57 | Y | 7.833333333 |
| 55 | Y | Prepandemic | 4 | N | Surveillance | 86 | M | HH | Y | NA | IV | D | NA | Supportive care | 4.5 | Dead | NA | Y | Missed | US | NA | NA | 2 | NA | NA | N | 37 |
| 56 | Y | Prepandemic | 4 | N | Surveillance | 78 | F | ARLD | Y | 17 | II | A | NA | Ablation | 15.67 | Dead | NA | Y | Consistent | US | 4.1 | NA | 0 | 4.23 | NA | Y | 5.633333333 |
| 57 | Y | Prepandemic | 4 | N | Incidental | 61 | M | ARLD | Y | 33 | IV | C | NA | Medical | 29.07 | Alive | Secondary care�routine | N | NA | NA | 2.47 | NA | 0 | 3.8 | NA | N | NA |
| 58 | Y | Prepandemic | 4 | N | Incidental | 71 | M | HCV | N | 28 | IIIA+IIIB | A | NA | Medical | 14.03 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 1 | 3.8 | 2.2 | N | NA |
| 59 | Y | Prepandemic | 4 | N | Surveillance | 70 | M | NAFLD | Y | 21 | I | A | NA | Ablation | 29.07 | Alive | NA | Y | Consistent | US | 0 | NA | 0 | 2.5 | NA | Y | 11.13333333 |
| 60 | Y | Prepandemic | 4 | N | Incidental | 71 | M | ARLD | Y | 22 | I | A | NA | TACE | 29.07 | Alive | Secondary care�acute | N | NA | NA | 1.6 | NA | 0 | 1.6 | NA | N | NA |
| 61 | Y | Prepandemic | 4 | N | Symptomatic | 48 | M | HCV | Y | 72 | IV | C | NA | Supportive care | 29.07 | Alive | NA | N | NA | NA | NA | NA | 0 | NA | NA | N | NA |
| 62 | Y | Prepandemic | 5 | N | Incidental | 75 | M | ARLD | Y | 31 | IV | C | NA | TACE | 28.83 | Alive | Secondary care�routine | Y | Consistent | NA | 1.83 | NA | 1 | 1.13 | NA | Y | 6.166666667 |
| 63 | Y | Prepandemic | 5 | N | Incidental | 73 | M | NAFLD | Y | 26 | I | A | NA | TACE | 28.83 | Alive | Primary care�routine | N | NA | NA | 1.6 | NA | 0 | 1.83 | 1.37 | N | NA |
| 64 | Y | Prepandemic | 5 | N | Incidental | 76 | M | No established CLD | N | 130 | IV | D | NA | Supportive care | 2.17 | Dead | Secondary care�routine | N | NA | NA | NA | NA | 2 | NA | NA | N | NA |
| 65 | Y | Prepandemic | 5 | N | Surveillance | 82 | F | NAFLD | Y | 18 | I | A | NA | Supportive care | 13.07 | Dead | NA | Y | Consistent | US | NA | NA | 0 | NA | NA | Y | 4.266666667 |
| 66 | Y | Prepandemic | 5 | N | Incidental | 74 | M | NAFLD | N | 80 | I | B | NA | SIRT | 22.8 | Dead | Primary care�routine | N | NA | NA | 1.73 | NA | 0 | 2.47 | NA | N | NA |
| 67 | Y | Prepandemic | 5 | N | Symptomatic | 79 | M | NAFLD | N | NA | IIIA+IIIB | D | NA | Supportive care | 0.93 | Dead | NA | N | NA | NA | NA | NA | 3 | NA | NA | N | NA |
| 68 | Y | Prepandemic | 5 | N | Surveillance | 61 | F | ARLD | Y | 18 | I | C | NA | Ablation | 28.6 | Alive | NA | Y | Consistent | AFP alone | 3 | NA | 2 | 3.67 | NA | Y | 6.166666667 |
| 69 | Y | Prepandemic | 5 | N | Incidental | 81 | M | No established CLD | N | 60 | IIIA+IIIB | C | NA | Supportive care | 3.4 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 3 | NA | NA | N | NA |
| 70 | Y | Prepandemic | 5 | N | Symptomatic | 82 | M | NAFLD | Y | 100 | IIIA+IIIB | C | NA | Supportive care | 7.1 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 71 | Y | Prepandemic | 5 | N | Incidental | 60 | M | NAFLD | Y | 41 | I | B | NA | OLTx | 28.37 | Alive | Secondary care�routine | Y | Consistent | NA | 1.13 | NA | 0 | 1.13 | NA | Y | 5.6 |
| 72 | Y | Prepandemic | 5 | N | Symptomatic | 83 | M | NAFLD | Y | 37 | I | C | NA | Supportive care | 7.8 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 73 | Y | Prepandemic | 5 | N | Incidental | 71 | F | ARLD | N | 14 | I | A | NA | Ablation | 28.37 | Alive | Secondary care�acute | N | NA | NA | 0 | NA | 0 | 2.5 | NA | N | NA |
| 74 | Y | Prepandemic | 5 | N | Incidental | 90 | M | NAFLD | Y | 33 | I | A | NA | Supportive care | 10.9 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 2 | NA | NA | N | NA |
| 75 | Y | Prepandemic | 5 | N | Symptomatic | 67 | M | NAFLD | Y | 14 | II | D | NA | Supportive care | 6.73 | Dead | NA | N | NA | NA | NA | NA | 3 | NA | NA | Y | NA |
| 76 | Y | Prepandemic | 5 | N | Symptomatic | 80 | M | No established CLD | N | 114 | I | C | NA | Supportive care | 5.47 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 77 | Y | Prepandemic | 5 | N | Incidental | 69 | M | ARLD | Y | 14 | I | A | NA | TACE | 28.13 | Alive | Secondary care�acute | Y | Inconsistent | NA | 4.93 | NA | 1 | 4.93 | NA | Y | 6.066666667 |
| 78 | Y | Prepandemic | 5 | N | Incidental | 78 | M | NAFLD | N | 25 | II | C | NA | TACE | 28.13 | Alive | Primary care�acute | N | NA | NA | 2.53 | NA | 1 | 3.17 | NA | N | NA |
| 79 | Y | Prepandemic | 6 | N | Incidental | 68 | F | No established CLD | N | 95 | IIIA+IIIB | C | NA | Supportive care | 17.17 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 2 | NA | NA | N | NA |
| 80 | Y | Prepandemic | 6 | N | Surveillance | 70 | M | NAFLD | Y | 23 | II | C | NA | Supportive care | 27.93 | Alive | NA | Y | Consistent | US | NA | NA | 1 | NA | NA | Y | 8.3 |
| 81 | Y | Prepandemic | 6 | N | Incidental | 87 | M | NAFLD | N | 100 | IIIA+IIIB | C | NA | Supportive care | 27.93 | Alive | Secondary care�acute | N | NA | NA | NA | NA | 2 | NA | NA | N | NA |
| 82 | Y | Prepandemic | 6 | N | Surveillance | 54 | M | HCV | Y | 40 | II | C | NA | TACE | 17.87 | Dead | NA | Y | Consistent | US | NA | NA | 0 | NA | NA | N | 26.7 |
| 83 | Y | Prepandemic | 6 | N | Incidental | 55 | M | HCV | Y | NA | IV | C | NA | Medical | 5.8 | Dead | Primary care�acute | N | NA | NA | NA | NA | 0 | NA | NA | N | NA |
| 84 | Y | Prepandemic | 6 | N | Incidental | 61 | F | HCV | Y | 20 | II | D | NA | Supportive care | 7.2 | Dead | Secondary care�acute | Y | Inconsistent | NA | NA | NA | 3 | NA | NA | Y | 0.733333333 |
| 85 | Y | Prepandemic | 6 | N | Incidental | 76 | F | PBC/AIH | Y | 30 | II | C | NA | SIRT | 20.3 | Dead | Secondary care�acute | N | NA | NA | 6.3 | NA | 1 | 5.47 | 0 | Y | NA |
| 86 | Y | Prepandemic | 6 | N | Incidental | 66 | M | ARLD | Y | 32 | II | D | NA | OLTx | 27.7 | Alive | Secondary care�acute | N | NA | NA | NA | NA | 3 | NA | NA | N | NA |
| 87 | Y | Prepandemic | 6 | N | Surveillance | 61 | F | HCV | Y | 21 | I | A | NA | Ablation | 27.7 | Alive | NA | Y | Consistent | US | NA | NA | 0 | NA | NA | Y | 6.8 |
| 88 | Y | Prepandemic | 6 | N | Symptomatic | 62 | F | HCV | Y | 19 | IV | D | NA | Supportive care | 1.13 | Dead | NA | Y | Inconsistent | NA | NA | NA | 3 | NA | NA | Y | 5.6 |
| 89 | Y | Prepandemic | 6 | N | Surveillance | 81 | M | NAFLD | Y | 40 | IV | C | NA | Supportive care | 8.87 | Dead | NA | Y | Consistent | US | NA | NA | 1 | NA | NA | Y | 6.1 |
| 90 | Y | Prepandemic | 6 | Y | Symptomatic | 82 | M | NAFLD | N | 49 | IV | D | NA | Supportive care | 0.8 | Dead | NA | N | NA | NA | NA | NA | 3 | NA | NA | NA | NA |
| 91 | Y | Prepandemic | 6 | N | Symptomatic | 77 | M | NAFLD | Y | 50 | IIIA+IIIB | B | NA | TACE | 27.47 | Alive | NA | N | NA | NA | 1.3 | NA | 0 | 1.33 | NA | N | NA |
| 92 | Y | Prepandemic | 6 | N | Incidental | 74 | M | NAFLD | N | 76 | I | C | NA | TACE | 19.1 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 2 | NA | NA | N | NA |
| 93 | Y | Prepandemic | 6 | N | Incidental | 50 | M | NAFLD | Y | 100 | IIIA+IIIB | B | NA | SIRT | 10.5 | Dead | Primary care�routine | N | NA | NA | 1.93 | NA | 0 | 1.73 | NA | N | NA |
| 94 | Y | Prepandemic | 6 | N | Symptomatic | 80 | F | ARLD | Y | 15 | I | D | NA | Supportive care | 2.63 | Dead | NA | N | NA | NA | NA | NA | 3 | NA | NA | N | NA |
| 95 | Y | Prepandemic | 6 | N | Symptomatic | 72 | M | HH | N | 50 | IIIA+IIIB | C | NA | SIRT | 27 | Alive | NA | N | NA | NA | 4.47 | NA | 1 | 5.27 | NA | N | NA |
| 96 | Y | Prepandemic | 6 | N | Surveillance | 55 | M | PBC/AIH | Y | 43 | IIIA+IIIB | C | NA | OLTx | 10.13 | Dead | NA | Y | Consistent | US | 1.8 | NA | 1 | 1.8 | NA | Y | 14.43333333 |
| 97 | Y | Prepandemic | 7 | N | Incidental | 91 | M | No established CLD | N | 96 | IIIA+IIIB | C | NA | Supportive care | 11.33 | Dead | Primary care�routine | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 98 | Y | Prepandemic | 7 | N | Surveillance | 76 | M | HH | N | 31 | II | B | NA | TACE | 26.8 | Alive | NA | Y | Consistent | US | 1.17 | NA | 0 | 1.53 | NA | N | 5.666666667 |
| 99 | Y | Prepandemic | 7 | N | Symptomatic | 79 | F | PBC/AIH | N | 12 | I | C | NA | Supportive care | 0.27 | Dead | NA | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |
| 100 | Y | Prepandemic | 7 | N | Incidental | 75 | M | No established CLD | N | 75 | IIIA+IIIB | C | NA | Supportive care | 10.47 | Dead | Secondary care�acute | N | NA | NA | NA | NA | 1 | NA | NA | N | NA |